SCYNEXIS, Inc. (SCYX) is a publicly traded Healthcare sector company. As of May 21, 2026, SCYX trades at $0.67 with a market cap of $54.43M and a P/E ratio of -1.39. SCYX moved +2.01% today. Year to date, SCYX is +4.82%; over the trailing twelve months it is -16.46%. Its 52-week range spans $0.57 to $1.62. Analyst consensus is buy with an average price target of $3.50. Rallies surfaces SCYX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Scynexis Raises $37.2M, Adds $16M, Extends Cash Runway to Mid-2029: Scynexis raised $37.2M in a private placement and added $16M on April 1, ending Q1 with $72.4M cash to fund operations into mid-2029. The company acquired SCY-770 for ADPKD and targets a Phase 2 proof-of-concept in Q4 2026, with Phase 1 IV SCY-247 topline data due in Q3 2026.
| Metric | Value |
|---|---|
| Price | $0.67 |
| Market Cap | $54.43M |
| P/E Ratio | -1.39 |
| EPS | $-0.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $1.62 |
| 52-Week Low | $0.57 |
| Volume | 57 |
| Avg Volume | 0 |
| Revenue (TTM) | $20.34M |
| Net Income | $-24.52M |
| Gross Margin | 0.00% |
2 analysts cover SCYX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.50.